TRIANA Biomedicines
Jesse Chen is a highly experienced biomedical professional currently serving as Co-Founder and Chief Technology Officer at TRIANA Biomedicines since January 2021. In addition, Jesse co-founded Avilar Therapeutics, where roles include Advisor and VP of Research since January 2020. Prior experience includes Entrepreneur-in-Residence at RA Capital Management, LLC, and various leadership positions at Kymera Therapeutics, including Senior Director of Discovery. Jesse's career began with significant contributions at Moderna Therapeutics, Millennium: The Takeda Oncology Company, and Massachusetts General Hospital, where work focused on cancer research and chemical genetic systems. Jesse holds a PhD in Biological Chemistry from the Massachusetts Institute of Technology and a BS in Biochemistry from Nanjing University.
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.